Since 1987, Tosoh Bioscience has repeatedly paved the way in bioseparations, firmly establishing itself as a global leader in liquid chromatography. With innovation at its core, Tosoh Bioscience has populated its impressive news feed with new product announcements and expansions. As a star player in Protein A Resins, Tosoh Bioscience was noted in a prime position to serve what is projected to be a $900 Million market by 2024.
In 2016, Tosoh Bioscience and The University of Akron (home to one of the world’s top-ranked polymer sciences programs) unveiled the Tosoh Polymer Chromatography Laboratory to support the study of polymers, nanomaterials, and biomaterials.
In 2017, a remarkable study was published in the Journal of the American Medical Association. Researchers found that HbA1c may not perform as accurately among patients with Sickle Cell Trait and could be leading to a fundamental underestimation of blood sugar control among that group. This study was conducted using assays published by Tosoh Bioscience, and has been applauded as having significant clinical implications for the treatment of patients with Sickle Cell Trait and Diabetes.
With a reliably productive track record, it's safe to assume that Tosoh Bioscience will continue to be an innovator in its field. In fact, the company's LinkedIn feed touts yet another addition to the product line, signaling continued innovation on the horizon.